Navigation Links
EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board
Date:9/2/2010

EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board -- VIENNA, Austria, September 2, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements Click to view news release full screen  

EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board

 

VIENNA, Austria, September 2, 2010 /PRNewswire/ -- EUCODIS Bioscience, a developer and manufacturer of customized enzymes announced today the appointment of two seasoned biotechnology executives to its Advisory Board. The new appointees are Dr. David Rozzell, founder of BioCatalytics (now Codexis) and currently CEO of Solidus Biosciences, and Dr. Ulf Bethke, COO of Miltenyi Biotec. Dr. Thomas Moser, Pontis Capital, and Harald Schuerz, Wiener Wachstumsfonds, will continue to serve on the realigned Advisory Board.

With its current members, EUCODIS Bioscience's Advisory Board will focus on providing guidance and advice in the areas of strategy, market and organization, strengthening the skills and experience of EUCODIS Bioscience's management team.

"I am extremely pleased to welcome two distinguished executives of the biotechnology industry to our Advisory Board," said Thomas Fischer, CEO EUCODIS Bioscience. "Dr. Rozzell as a successful founder and entrepreneur in the enzyme industry, and Dr. Bethke with entrepreneurial mindset and his track record in biotechnology manufacturing and operations, bring to EUCODIS Bioscience a wealth of hands-on experience and operational knowledge. Having these seasoned executives on our Advisory Board will be a tremendous asset to the Company as our customer base is growing rapidly. We will continue to expand our portfolio, and are aggressively addressing new business opportunities in the pharmaceutical, bioproducts, cosmetics, and other industries."

Dr. David Rozzell is President and CEO of Solidus Biosciences, a company providing research and analytical services to the pharmaceutical and cosmetics industry, enhancing their development productivity. Prior to joining Solidus as CEO, he was the Founder and CEO of enzyme developer BioCatalytics, which he grew to a leader in its field until the company was successfully sold to Codexis in 2007. Before founding BioCatalytics, Dr. Rozzell was President and COO of Exogene.

Dr. Ulf Bethke is Chief Operating Officer of Miltenyi Biotec, one of Germany's most successful biotechnology companies. Before joining Miltenyi Biotec in 1994, he was responsible for the development and production of therapeutic monoclonal antibodies at Biotest, a German pharmaceutical company.

Dr. Thomas Moser is Managing Partner at Pontis Capital, an Austrian venture capital company. He has 10 years of experience as an investment manager, overseeing the whole investment life-cycle, from deal acquisition through active management of portfolio companies to financing and implementation of the exit strategy.

Harald Schuerz is CEO of Wiener Wachstumsfonds, an Austrian venture capital fund focusing on innovative, fast growing companies. Before joining Athena, he held executive positions at leading Austrian banks where he was responsible for venture capital investments and international financing.

About EUCODIS Bioscience

EUCODIS Bioscience provides enzymes to the chemical, health care, and other industries, and offers custom-engineering and custom-manufacturing services.

Customers use EUCODIS Bioscience' enzymes and services to make their manufacturing processes more efficient and cleaner and to introduce products with superior properties. The Company's technology of in vivo-recombination is a proven tool for the directed evolution of enzymes that perform to customers' specific requirements.

Enzymes are proteins that catalyze highly specific chemical reactions, offering a safer, cleaner, and competitive alternative to traditional chemistry. They are at the center of industrial, or "white" biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

For more information, please visit http://www.eucodisbioscience.com Company contact EUCODIS Bioscience: Thomas Fischer, MBA CEO EUCODIS Bioscience Campus Vienna Biocenter II Viehmarktgasse 2 a/ 2 OG A-1030 Vienna AUSTRIA +43-1-8900804 office@eucodisbioscience.com Media contact EUCODIS Bioscience: Frank Butschbacher Investor Relations & Communications http://www.butschbacher.net +43-650-7844940 office@butschbacher.net
'/>"/>

SOURCE EUCODIS Bioscience
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
2. EUCODIS Bioscience Appoints Thomas Fischer as New CEO
3. EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
4. EUCODIS Bioscience Launches Lipase Portfolio
5. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
6. EUCODIS Bioscience Signs Research Agreement With Genencor
7. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
8. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
9. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
10. Signum Biosciences Names Braham Shroot as Chief Executive Officer
11. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... MA to soon resume cervical and lumbar disc production, company President, Jake Lubinski ... surgeons who are implanting the AxioMed disc in Cologne and Karlsruhe to discuss ...
(Date:12/5/2016)... 5, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or ... Data and Safety Monitoring Board (DSMB) for the ... disease (CVD) patients has completed a second planned ... continue as planned without any modifications. The DSMB ... safety or efficacy concerns were identified. The DSMB ...
(Date:12/5/2016)... Research and Markets has announced the ... Technologies, Markets and Companies" to their offering. ... , , ... human genome variations, development of sequencing technologies, and their applications. ... companies developing them. Various applications of sequencing are described including ...
(Date:12/4/2016)... San Francisco, CA (PRWEB) , ... December 03, ... ... scientific grants to ground-breaking microbiome studies. A microbiome impact grant award has been ... study the effect of heavy smoking and drinking on the oral microbiome. Grant ...
Breaking Biology Technology:
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
Breaking Biology News(10 mins):